[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapse-acute-myeloid-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapse-acute-myeloid-leukemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100630365","phase-1-aclarubicin-plus-with-azacitidine-and-venetoclax-in-the-treatment-of-acute-myeloid-leukemia-100630365",false,"NCT07486726","Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","A Multicenter, Open-Label, Phase 1\u002F2 Clinical Study of the Safety and Efficacy of Aclarubicin Combined With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form.\n2. Age 18 or above.\n3. Diagnosis (the diagnose is based on the 5th edition of the WHO classification of hematolymphoid tumors):\n\n   1. Phase I cohort: Adults ≥18 years with newly diagnosed AML who's not a candidate for intensive chemotherapy (criteria include age ≥75, significant cardiac\u002Fpulmonary\u002Fhepatic\u002Frenal comorbidities, CGA assessment unfit for IC, etc.) or declines.\n   2. Phase II cohort A: Adults ≥18 years with newly diagnosed AML who's not a candidate for intensive chemotherapy (criteria include age ≥75, significant cardiac\u002Fpulmonary\u002Fhepatic\u002Frenal comorbidities, CGA assessment unfit for IC, etc.) or declines.\n   3. Phase II cohort B: Adults ≥18 years with relapsed\u002Frefractory AML after intensive chemotherapy (Exclude patients with FLT3 or IDH1\u002F2 mutations who have not previously received targeted therapy).\n4. Performance status \\\u003C 3 (ECOG Scale).\n5. Estimated survival ≥ 3 months.\n6. White blood cell (WBC) count \\\u003C 25 × 10\\^9 cells\u002FL (hydroxyurea is permitted to control WBC count before treatment).\n7. Adequate liver and renal function as defined by the following criteria:\n\n   1. Total serum bilirubin \\\u003C 2.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI\n   2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\\u003C 2.5 x ULN, unless due to the underlying leukemia approved by the PI\n   3. Creatinine clearance ≥50 mL\u002Fmin\n8. Ability to swallow\n9. Phase II Cohort B: Subjects have recovered from prior treatment toxicity to less than Grade 2 (per CTCAE v6.0), excluding the influence of the underlying disease. The following are excluded: alopecia, fatigue, hyperpigmentation, hypothyroidism stabilized with hormone replacement therapy, and peripheral neuropathy following chemotherapy.\n10. Phase II Cohort B: Washout period from first dose of prior anti-cancer therapy\n\n    1. at least 2 weeks after completion of cytotoxic chemotherapy\n    2. at least 5 half-lives for non-cytotoxic drugs (if the 5 half-lives exceed 4 weeks, the washout period will still be calculated as 4 weeks). If the half-life is unclear, a washout period of \\>4 weeks will be considered\n    3. at least 2 weeks after the first dose of anti-cancer traditional Chinese medicine.\n11. Subjects of reproductive potential must use effective contraceptive measures from the time they sign the informed consent form until 6 months after the last dose of the trial medication. Furthermore, male subjects of reproductive potential must refrain from sperm donation from the time they sign the informed consent form until 6 months after the last dose of the trial medication.\n\nExclusion Criteria:\n\n1. Prior therapies\n\n   1. Phase I cohort: Patients with prior therapy are not eligible. Patients with a history of myeloproliferative disorders (MPNs), including primary myelofibrosis (PMF), polycythemia vera (PV), chronic myeloid leukemia (CML) excluding essential thrombocythemia (ET); or myelodysplasia-myeloproliferative neoplasms (MDS-MPNs), including chronic monocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), and acute promyelocytic leukemia (APL) are not eligible.\n\n      Prior hydroxyurea or cytarabine given for purposes of cytoreduction is also allowed. Prior all trans-retinoic acid given for presumed acute promyelocytic leukemia is also allowed.\n   2. Phase II cohort A: Same as for Phase I cohort.\n   3. Phase II cohort B: Patients relapsed\u002Frefractory to prior lower intensity therapy for AML are not eligible. No restriction on number of prior therapies.\n2. Patients suitable for and willing to receive intensive induction chemotherapy (for Phase I and Phase II cohort A).\n3. Congenital long QT syndrome or QTcF \\>450 msec (male), \\>470 msec (female). Repeat EKGs after correction of electrolytes or discontinuation of QT prolonging medications are allowed to meet entry criteria. In cases where QTcF \\>450\u002F470 msec is considered to be falsely increased due to inaccurate automated reading and not clinically significant (e.g. due to bundle branch block), patients are still eligible if cardiologist reviews and documents that QTcF is ≤ 450 msec when manually measured.\n4. Active serious infection not controlled by systemic antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment).\n5. Active Grade III-V cardiac failure as defined by the New York Heart Association Criteria.\n6. Active central nervous system leukemia, extramedullary AML (except liver\u002Fspleen\u002Flymph nodes)\n7. Known human immunodeficiency virus (HIV) seropositive. Known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection.\n8. Patients who have received an allo-HCT within 60 days of first receiving study medication must discontinue all immunosuppressants during study treatment.\n9. Patients who have previously received CAR-T therapy.\n10. Subjects with malabsorption syndrome or other comorbidities that prevent them from swallowing capsules or taking medications via the enteral route.\n11. Patients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI.\n12. Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry. Prior recent treatment with corticosteroids, hydroxyurea and\u002For cytarabine (given for cytoreduction) is permitted.\n13. Pregnant \u002Flactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception throughout the study period and for at least 6 months after the last dose of study drugs. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 6 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control throughout the study period and for at least 6 months after the last dose of study drugs.","ALL","18 Years",{"count":19,"type":20},112,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Acute myeloid leukemia Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual incidence rate of AML is 4.1 per 100000 people in the US and is higher in patients older than 65 years. There has been a steady improvement in survival over the decades, more noticeably so in younger patients and in the last decade. Azacitidine and Venetoclax is now the standard treatment of newly diagnosed AML ineligible for intensive chemotherapy, while still facing the dilemma of relapse and refractory disease.\n\nAnthracycline-based chemotherapeutics were wildly used in the treatment of fit AML patients. While the cardiovascular toxicity leading to morbidity and mortality limited the use of daunorubicin\u002Fidarubicin in unfit patients. Aclarubicin, also known as aclacinomycin A, is an anthracycline type of antibiotic with significant anti-cancer properties. Previous studies have shown that aclarubicin only induces histone eviction without causing DNA damage, and it stands out in pre-clinical models and clinical studies, as it potently kills AML cells. Meanwhile, aclarubicin lacks cardiotoxicity, and can be safely administered even after the maximum cumulative dose of either doxorubicin or idarubicin has been reached. CAG regimen, combined with low-dose cytarabine, aclarubicin and G-CSF has been widely used in China and Japan for treatment of AML.\n\nThe purpose of this study is to determine the maximum tolerated dose, safety and efficacy of aclarubicin combined with azacitidine and venetoclax for subjects with newly diagnosed and relapsed \u002Frefractory AML.",[27,28,29],"Acute Myeloid Leukemia (AML)","Relapse Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia (AML)",[31,32,33,34],"acute myeloid leukemia","Aclarubicin","ineligible for intensive chemotherapy","Azacitidine and Venetoclax","NOT_YET_RECRUITING","2026-03-17",{"date":38,"type":39},"2026-03-20","ACTUAL",{"date":41,"type":20},"2026-03-15",{"date":43,"type":20},"2028-10",{"name":45,"class":46},"Shanghai Jiao Tong University School of Medicine","OTHER",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100550439","phase-2-vmacdli-treatment-of-patients-with-relapse-of-aml-after-allo-hsct-100550439","NCT06447090","VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT","Study on the Efficacy and Safety of VMAC Combined With Donor Lymphocyte Infusion (DLI) in the Treatment of Patients With Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","VMAC+DLI","Inclusion Criteria:\n\n1. Patients with AML confirmed by bone marrow morphology and morphological recurrence after allo-HSCT (proportion of bone marrow morphological blast cells ≥5%);\n2. Age ≥18 years and ≤65 years old, regardless of gender;\n3. Eastern Oncology The evaluation of physical status of the cooperative group (ECOG-PS) is 0-2 points;\n4. An informed consent form must be signed before the start of the research procedure, and the patient himself or his immediate family members must sign the informed consent form. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family member will sign the informed consent form.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria shall not be enrolled in this study:\n\n* 1\\) Secondary transplant patients;\n* 2\\) Have a history of tumor and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer , basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN) or prostate intraepithelial carcinoma (PIN);\n* 3\\) Serological reactions of known HIV, active hepatitis B, and active hepatitis C virus positive or syphilis positive;\n* 4\\) Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring;\n* 5\\) Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment;\n* 6\\) Active heart disease, definition One or more of the following:\n\n  1. Long QTc syndrome or QTc interval \\>480ms;\n  2. Complete left bundle branch block, II or III degree atrioventricular block;\n  3. Need for drug treatment or History of severe arrhythmia with clinical symptoms;\n  4. New York Heart Association classification ≥ II;\n  5. Left ventricular ejection fraction less than 50%;\n  6. Myocardial infarction, unstable angina, severe myocardial infarction within 6 months before enrollment History of unstable ventricular arrhythmias or any other arrhythmias requiring treatment, clinically severe pericardial disease, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.\n* 7\\) Transplantation from an unrelated donor;\n* 8\\) Those deemed not suitable for enrollment by the researcher.","65 Years",{"count":58,"type":20},30,[24],"This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic stem cell transplantation.\n\nThe main questions it aims to answer are:\n\nThe safety and efficacy of VMAC combined with DLI in the treatment of allo HSCT recurrence in AML patients;",[28],[63],"Mitoxantrone liposome","RECRUITING","2024-06-03",{"date":67,"type":39},"2024-06-06",{"date":69,"type":39},"2024-04-12",{"date":71,"type":20},"2027-10-31",{"name":73,"class":46},"Institute of Hematology & Blood Diseases Hospital, China",1]